Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. More Details
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Santhera Pharmaceuticals Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SANN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SANN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
7 Day Return
1 Year Return
Return vs Industry: SANN underperformed the Swiss Biotechs industry which returned 1.3% over the past year.
Return vs Market: SANN underperformed the Swiss Market which returned -0.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Santhera Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StBreakeven On The Horizon For Santhera Pharmaceuticals Holding AG (VTX:SANN)
4 months ago | Simply Wall StHere's Why Santhera Pharmaceuticals Holding (VTX:SANN) Can Afford Some Debt
6 months ago | Simply Wall StSanthera Pharmaceuticals Holding AG's (VTX:SANN) Profit Outlook
Is Santhera Pharmaceuticals Holding undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SANN (CHF2.7) is trading below our estimate of fair value (CHF210.9)
Significantly Below Fair Value: SANN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SANN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: SANN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SANN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SANN is overvalued based on its PB Ratio (147.2x) compared to the CH Biotechs industry average (3x).
How is Santhera Pharmaceuticals Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SANN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SANN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SANN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SANN's revenue (39.3% per year) is forecast to grow faster than the Swiss market (4.6% per year).
High Growth Revenue: SANN's revenue (39.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SANN's Return on Equity is forecast to be high in 3 years time
How has Santhera Pharmaceuticals Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SANN is currently unprofitable.
Growing Profit Margin: SANN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SANN is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Accelerating Growth: Unable to compare SANN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SANN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).
Return on Equity
High ROE: SANN has a negative Return on Equity (-11380.95%), as it is currently unprofitable.
How is Santhera Pharmaceuticals Holding's financial position?
Financial Position Analysis
Short Term Liabilities: SANN's short term assets (CHF36.6M) exceed its short term liabilities (CHF30.0M).
Long Term Liabilities: SANN's short term assets (CHF36.6M) do not cover its long term liabilities (CHF69.9M).
Debt to Equity History and Analysis
Debt Level: SANN's debt to equity ratio (27665.2%) is considered high.
Reducing Debt: Insufficient data to determine if SANN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SANN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SANN is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 11.9% per year.
What is Santhera Pharmaceuticals Holding current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SANN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SANN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SANN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SANN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SANN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dario Eklund (52 yo)
Mr. Dario Eklund has been Chief Executive Officer at Santhera Pharmaceuticals Holding AG since December 1, 2019. He served as Head of Global Business Operations at Vifor Pharma Ltd. since 2014. He served a...
CEO Compensation Analysis
Compensation vs Market: Dario's total compensation ($USD1.80M) is above average for companies of similar size in the Swiss market ($USD494.49K).
Compensation vs Earnings: Insufficient data to compare Dario's compensation with company performance.
|Chief Executive Officer||1.08yrs||CHF1.61m||no data|
|Founder & Director||3.75yrs||no data||0.41% |
|Chief Financial Officer||0.75yr||no data||no data|
|Executive VP||5.92yrs||no data||no data|
|Head of External Communications||no data||no data||no data|
|Head of Business Development & Executive VP||no data||no data||no data|
|Head of the Puldysa Global Program||no data||no data||no data|
Experienced Management: SANN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|Founder & Director||3.75yrs||no data||0.41% |
|Non-Executive Independent Director||14.25yrs||CHF274.09k||0.19% |
|Non-Executive Independent Director||3.75yrs||CHF219.27k||0.0049% |
|Non-Executive Independent Chairman||3.75yrs||CHF296.31k||0.059% |
|Non Executive Independent Director||3.75yrs||CHF208.31k||0.035% |
Experienced Board: SANN's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 82.8%.
Santhera Pharmaceuticals Holding AG's company bio, employee growth, exchange listings and data sources
- Name: Santhera Pharmaceuticals Holding AG
- Ticker: SANN
- Exchange: SWX
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF54.844m
- Shares outstanding: 20.31m
- Website: https://www.santhera.com
Number of Employees
- Santhera Pharmaceuticals Holding AG
- Hohenrainstrasse 24
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SANN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Nov 2006|
|S3F||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Nov 2006|
|SPHD.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Nov 2006|
|0QN1||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Nov 2006|
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 18:11|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.